Csnk1g2 Antibody

What is Csnk1g2 and what are its primary biological functions?

Csnk1g2 (Casein kinase 1 gamma 2) is a serine/threonine protein kinase belonging to the casein kinase family. These kinases are characterized by their preferential utilization of acidic proteins such as caseins as substrates . Csnk1g2 functions primarily as:

• An inhibitor of receptor-interacting kinase 3 (RIPK3), attenuating RIPK3-mediated necroptosis

• A participant in Wnt signaling pathways

• A phosphorylator of multiple proteins including COL4A3BP/CERT, MTA1, and SMAD3

• A regulator of SMAD3-mediated TGF-beta responses through phosphorylation that promotes ligand-dependent ubiquitination and subsequent proteasome degradation

• A controller of reactive oxygen species (ROS) levels

In the testis specifically, it plays a crucial role in preventing premature aging by suppressing necroptosis through direct binding to RIPK3, which is triggered by auto-phosphorylation at serine 211/threonine 215 sites in its C-terminal domain .

Which tissue types express Csnk1g2 and at what levels?

Based on expression studies in mouse tissues, Csnk1g2 shows a distinct tissue distribution pattern:

• Highest expression: Testis

• Moderate expression: Lung and spleen

• Low expression: Brain, heart, liver, ovary, and intestine

In human tissues, immunohistochemical analysis has confirmed Csnk1g2 expression in the seminiferous tubules of the testis, with expression patterns overlapping with RIPK3 . This co-expression is particularly evident in spermatogenic cells and Sertoli cells, two major cell types in the seminiferous tubules .

What applications are Csnk1g2 antibodies validated for?

Commercial Csnk1g2 antibodies have been validated for multiple applications:

• Western Blot (WB): For detecting Csnk1g2 protein expression levels in tissue or cell lysates

• Immunohistochemistry (IHC): Particularly for paraffin-embedded tissues (IHC-P)

• Immunoprecipitation (IP): For isolating Csnk1g2 and its binding partners

• Immunofluorescence: For visualizing cellular localization

These applications have been validated primarily in human and mouse samples, with most commercial antibodies demonstrating reactivity to both species due to the high sequence conservation .

How should I select an appropriate Csnk1g2 antibody for my research?

When selecting a Csnk1g2 antibody, consider these factors:

• Species reactivity: Ensure the antibody recognizes your target species. Most commercial antibodies react with human and mouse Csnk1g2, with approximately 81% sequence identity between these species .

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IHC, IP, etc.) .

• Clonality:

  • Polyclonal antibodies (like those described in the search results) offer good sensitivity but may have batch-to-batch variation

  • Monoclonal antibodies provide higher specificity and consistency between lots

• Immunogen information: Review what portion of the protein was used as immunogen. For example, some antibodies target the C-terminal region (aa 300 to C-terminus) , while others target specific peptide sequences (e.g., FDKKGGKGETEEGRRMSKAGGGRSSHGIRSS) .

• Validation evidence: Look for antibodies with validation in knockout systems or other specificity controls .

What are typical working dilutions for Csnk1g2 antibodies in common applications?

Based on commercial antibody datasheets, recommended working dilutions include:

Additional application notes indicate that for IHC-Paraffin applications, HIER pH 6 retrieval is recommended for optimal results .

What controls should I include when validating a Csnk1g2 antibody for my experimental system?

For rigorous validation of Csnk1g2 antibodies, include these controls:

• Positive controls:

  • Tissues with known high expression (testis samples)

  • Overexpression systems (e.g., CSNK1G2 over-expressed in HEK293T cells with a C-terminal tag)

• Negative controls:

  • Knockout tissues/cells (Csnk1g2-knockout mouse tissues)

  • Vector-only transfected cells for comparison with overexpression systems

  • Primary antibody omission to assess secondary antibody specificity

  • Isotype controls to assess non-specific binding

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • siRNA knockdown samples to demonstrate signal reduction

For example, in a study examining endogenous CSNK1G2 in mouse testis, researchers immunoprecipitated with an anti-CSNK1G2 antibody and confirmed specificity by comparing results with Csnk1g2 knockout littermates, which showed no precipitation of either CSNK1G2 or its binding partner RIPK3 .

How can I optimize the detection of Csnk1g2 in testicular tissue by immunohistochemistry?

For optimal Csnk1g2 detection in testicular tissue:

• Fixation and processing:

  • Use 10% neutral buffered formalin for fixation

  • Limit fixation time to 24-48 hours to prevent overfixation

  • Process and embed tissue using standard paraffin protocols

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) at pH 6 is recommended specifically for Csnk1g2 antibodies

  • Citrate buffer (10mM, pH 6.0) heating for 20 minutes in a pressure cooker or water bath

• Antibody incubation:

  • Dilute primary antibody in the range of 1:200-1:500

  • Incubate overnight at 4°C for optimal sensitivity

  • For detection, use appropriate species-specific secondary antibody systems

• Controls and counterstaining:

  • Include positive control (normal testis) and negative control (Csnk1g2 knockout if available)

  • Counterstain with hematoxylin for nuclear visualization

  • When studying aging effects, include both young and old testis samples for comparison

• Co-localization studies:

  • Consider dual staining with RIPK3 antibodies to demonstrate overlapping expression patterns in seminiferous tubules

This approach has successfully demonstrated Csnk1g2 expression in both mouse and human testicular seminiferous tubules .

What methods can be used to study the interaction between Csnk1g2 and RIPK3?

To investigate the Csnk1g2-RIPK3 interaction:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate endogenous Csnk1g2 from testis extracts using anti-Csnk1g2 antibody

  • Detect co-precipitated RIPK3 by western blot

  • Verify specificity using Csnk1g2 knockout tissues as negative controls

  • Alternative approach: IP with anti-RIPK3 antibody and detect Csnk1g2

• Recombinant protein interaction assays:

  • Express tagged versions of Csnk1g2 (e.g., Myc-tagged) in cell systems like HEK293T

  • Immunoprecipitate using tag-specific antibodies (anti-Myc)

  • Elute with antigenic peptide (0.5 mg/ml) or directly in SDS loading buffer

  • Analyze binding partners by mass spectrometry or western blot

• Functional interaction studies:

  • Compare necroptosis response in wild-type vs. Csnk1g2 knockout cells upon stimulation with necroptosis inducers like TSZ

  • Rescue experiments: reintroduce wild-type or mutant Csnk1g2 to knockout cells

  • Analyze phosphorylation status of RIPK3 using phospho-specific antibodies

• In vivo validation:

  • Double knockout studies (e.g., Csnk1g2/Ripk3 double knockout) to demonstrate functional relationship

  • Testing RIPK1 kinase inhibitor effects on Csnk1g2 knockout phenotypes

These methods have successfully demonstrated that Csnk1g2 directly binds to RIPK3, with binding triggered by auto-phosphorylation at specific sites in the Csnk1g2 C-terminal domain .

How can I analyze Csnk1g2 phosphorylation states and their functional significance?

To study Csnk1g2 phosphorylation:

• Sample preparation for phosphoprotein preservation:

  • Add phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and β-glycerophosphate) to all buffers

  • Use rapid extraction methods and maintain samples at 4°C

  • For tissues, snap freeze immediately after collection

• Phosphorylation site detection:

  • Immunoprecipitate Csnk1g2 using specific antibodies

  • Perform tryptic digestion following established protocols:

    • Dissolve samples in 2M urea, 50 mM ammonium bicarbonate, pH 8.0

    • Reduce with 2 mM DTT at 56°C for 30 min

    • Alkylate with 10 mM iodoacetamide in dark for 1 hr

    • Digest with sequencing grade modified trypsin (1:40 enzyme to protein ratio) at 37°C overnight

  • Analyze digested peptides by LC-MS/MS using an analytical capillary column (50 μm × 15 cm) packed with 5 μm spherical C18 reversed phase material

• Functional analysis of phosphosites:

  • Generate phosphomimetic (S/T to D/E) and phosphodeficient (S/T to A) mutants of key sites (e.g., serine 211/threonine 215)

  • Test mutants' ability to bind RIPK3 and inhibit necroptosis

  • Compare wild-type and mutant Csnk1g2 in rescue experiments

• Phosphospecific antibodies:

  • If available, use phospho-specific antibodies to detect specific phosphorylation events

  • For studying necroptosis activation, use phospho-MLKL (Ser358) antibodies as a downstream marker

This approach has identified that auto-phosphorylation at serine 211/threonine 215 sites in Csnk1g2's C-terminal domain is crucial for triggering RIPK3 binding .

What are the appropriate experimental designs for studying Csnk1g2's role in aging-related processes?

To investigate Csnk1g2's role in aging, particularly in testicular aging:

• Age-comparative studies:

  • Compare tissues from young and old subjects (both human and mouse)

  • For humans, analyze testis samples from different age groups (e.g., 30-year-old vs. 80+ year-old men)

  • Document histological changes in seminiferous tubules and cell composition

• Knockout model characterization:

  • Generate and analyze Csnk1g2-knockout mice across different age points

  • Compare with wild-type littermates to assess premature aging phenotypes

  • Document histological changes and molecular markers of aging

• Rescue experiments:

  • Perform genetic rescue (double knockout of Csnk1g2/Ripk3)

  • Test pharmacological rescue using RIPK1 kinase inhibitor-containing diets

• Molecular markers assessment:

  • Analyze necroptosis activation markers like phospho-MLKL in young vs. aged tissues

  • Compare these markers between wild-type and knockout animals

  • Include analysis of oxidative stress markers and tissue-specific functional parameters

• Translational relevance:

  • Compare findings between mouse models and human samples

  • Correlate molecular markers with histopathological findings

  • Consider potential therapeutic implications

This approach has successfully demonstrated that Csnk1g2-knockout mice show enhanced necroptosis and premature testis aging, a phenotype rescued by either Ripk3 gene knockout or RIPK1 inhibition, suggesting an evolutionarily conserved testis-aging program mediated by RIPK3 and attenuated by Csnk1g2 .

What are common issues when using Csnk1g2 antibodies and how can they be resolved?

Common issues and solutions include:

• High background in immunohistochemistry:

  • Increase antibody dilution (try 1:500 instead of 1:200)

  • Optimize blocking conditions (use 5-10% serum from secondary antibody species)

  • Include 0.1-0.3% Triton X-100 in blocking solution to reduce non-specific binding

  • Ensure proper antigen retrieval (HIER pH 6 as recommended)

  • Reduce primary antibody incubation time or incubate at 4°C overnight

• Weak or no signal in Western blot:

  • Verify sample preparation (proper lysis buffer with protease inhibitors)

  • Confirm protein loading (25-50 μg total protein per lane)

  • Test different antibody concentrations within the recommended range (0.04-0.4 μg/ml)

  • Increase exposure time during detection

  • Use tissues known to have high expression (testis) as positive control

• Multiple bands in Western blot:

  • Verify if bands represent isoforms, degradation products, or non-specific binding

  • Use Csnk1g2 knockout samples as negative controls

  • Compare with overexpression systems showing the correct molecular weight

  • Test different blocking agents (5% non-fat milk vs. 5% BSA)

• Failed immunoprecipitation:

  • Optimize lysis conditions to preserve protein-protein interactions

  • Try different antibody amounts (1-5 μg per IP reaction)

  • Include proper controls (IgG control, input sample)

  • For co-IP of RIPK3, ensure proper cell stimulation conditions to induce the interaction

How can I differentiate between different casein kinase family members in my experiments?

To distinguish between different casein kinase family members:

• Antibody selection:

  • Choose antibodies raised against unique regions with minimal sequence homology

  • For Csnk1g2, antibodies targeting the C-terminal domain (aa 300 to C-terminus) offer good specificity

  • Verify reported cross-reactivity with other casein kinase family members

• Expression pattern verification:

  • Compare tissue distribution (Csnk1g2 shows highest expression in testis)

  • Use tissue-specific expression as an internal control

• Molecular weight confirmation:

  • Compare observed molecular weights on Western blots with predicted weights

  • Use overexpression systems with tagged versions for size verification

• Functional validation:

  • Design experiments that test isoform-specific functions

  • For Csnk1g2, test RIPK3 binding and necroptosis inhibition

  • Use knockout/knockdown systems for specificity confirmation

• Mass spectrometry identification:

  • For ultimate specificity, analyze immunoprecipitated proteins by mass spectrometry

  • Follow established protocols for tryptic digestion and LC-MS/MS analysis

What is the best approach for studying Csnk1g2 in models of cellular stress or disease?

For studying Csnk1g2 in stress or disease models:

• Necroptosis induction models:

  • Treat cells with TSZ (TNF-α, Smac mimetic, and z-VAD-fmk) to induce necroptosis

  • Compare responses between wild-type and Csnk1g2-deficient cells

  • Monitor cell death using appropriate assays (e.g., LDH release, PI staining)

• Aging and stress models:

  • Compare young versus aged tissues (e.g., testis from young vs. old mice or humans)

  • Analyze oxidative stress markers alongside Csnk1g2 expression/activity

  • Assess phospho-MLKL as a downstream marker of necroptosis activation

• Disease-relevant models:

  • For testicular disorders, consider models of testicular torsion or inflammation

  • Analyze human samples from relevant pathological conditions

  • Study Csnk1g2 expression in relation to disease progression markers

• Pharmacological interventions:

  • Test effects of RIPK1 kinase inhibitors on Csnk1g2-deficient phenotypes

  • Consider small molecule modulators of casein kinase activity

  • Analyze potential therapeutic implications of Csnk1g2 modulation

• Molecular analyses:

  • Monitor changes in Csnk1g2 phosphorylation status under stress conditions

  • Analyze Csnk1g2-RIPK3 interaction dynamics during stress/disease progression

  • Investigate downstream signaling events and their temporal regulation

This approach has successfully demonstrated the role of Csnk1g2 in preventing necroptosis-mediated testis aging and provided insights into potential intervention strategies .

What are emerging techniques for studying Csnk1g2 beyond traditional antibody-based methods?

Emerging approaches include:

• CRISPR-Cas9 genome editing:

  • Generate precise Csnk1g2 knockout or knockin cell lines

  • Create models with tagged endogenous Csnk1g2 for live imaging

  • Introduce specific mutations in phosphorylation sites to study functional consequences

• Proximity labeling techniques:

  • BioID or TurboID fusion proteins to identify proximal interactors of Csnk1g2

  • APEX2-based proximity labeling for subcellular interaction mapping

  • Combine with mass spectrometry for unbiased interactome analysis

• Live-cell imaging approaches:

  • Fluorescent protein fusions to monitor Csnk1g2 dynamics

  • FRET-based sensors to detect Csnk1g2-RIPK3 interactions in real-time

  • Photoactivatable or photoconvertible tags for pulse-chase studies

• Single-cell analysis:

  • Single-cell RNA-seq to analyze cell-type-specific expression patterns

  • Mass cytometry for protein-level analysis in heterogeneous tissues

  • Spatial transcriptomics to map expression within complex tissues like testis

• In silico approaches:

  • Molecular dynamics simulations of Csnk1g2-RIPK3 interactions

  • Structure-based drug design for specific modulators

  • Systems biology modeling of necroptosis regulation networks

These emerging technologies will complement traditional antibody-based approaches and provide deeper insights into Csnk1g2 function in normal physiology and disease states.

How might findings on Csnk1g2's role in testicular aging translate to other aging-related disorders?

Potential translational implications include:

• Broader relevance to tissue aging:

  • Investigate if the Csnk1g2-RIPK3 regulatory axis functions similarly in other tissues

  • Study whether necroptosis inhibition by Csnk1g2 is a conserved anti-aging mechanism

  • Analyze tissue-specific expression patterns and aging phenotypes

• Neurodegenerative diseases:

  • Explore Csnk1g2's role in brain, where necroptosis contributes to neurodegeneration

  • Investigate potential connections to conditions like Alzheimer's or Parkinson's disease

  • Study brain-specific Csnk1g2 knockout models for age-related phenotypes

• Cardiovascular aging:

  • Examine Csnk1g2 expression and function in aging cardiac and vascular tissues

  • Study potential protective roles against age-related cardiovascular deterioration

  • Analyze RIPK3-mediated necroptosis in cardiovascular aging contexts

• Therapeutic development:

  • Develop RIPK inhibitors as potential anti-aging therapeutics

  • Explore Csnk1g2 activation strategies to attenuate necroptosis

  • Consider tissue-specific delivery approaches for targeted intervention

• Biomarker potential:

  • Evaluate Csnk1g2 expression or phosphorylation status as aging biomarkers

  • Analyze phospho-MLKL as a downstream marker of necroptosis activation across tissues

  • Develop diagnostic assays for premature aging phenotypes

The evolutionary conservation of the testis-aging program regulated by Csnk1g2-attenuated necroptosis between mice and humans suggests potential broader relevance to aging processes .